About Dravite Therapeutics
Dravite Therapeutics is a private company based in San Francisco, California, incorporated in 2025 in Delaware. It has reported $67,983,325 raised in two offerings on Form D since June 2026. Its chief executive is Matthew Moore.
Funding Rounds (SEC Form D)
| First sale | Filed with SEC | Amount sold | Investors | Avg. check | Terms | Filing |
|---|---|---|---|---|---|---|
| Aug 21, 2026 | Sep 3, 2026 | $52,999,992fully sold | 11 | $4.8M | EquityRule 506(b) | Form D ↗ |
| Apr 20, 2026 | Jun 24, 2026amended Jul 28, 2026 | $14,983,333fully sold | 8 | $1.8M | EquityRule 506(b) | Form D/A ↗1 earlier filing |
| Total, two offerings | $67,983,325 | |||||
First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.
Leadership Team
Executive officers and directors listed on Dravite Therapeutics's Form D filed Sep 3, 2026.
RG
Rishi Gupta
Director
MM
Matthew Moore
President and CEO, director
JS
Joseph Sum
Executive officer and director
BK
Barbara Kosacz
Director
SK
Sandeep Kulkarni
Director
JG
Jeremy Goldberg
Director